journal article·2025

Self-generating electricity system driven by aqueous humor flow and trabecular meshwork contraction motion activated BCKa for glaucoma intraocular pressure treatment

Ruiqi Wang, Haiying Wei, Yuying Shi, Cao Wang, Zhenqiang Yu, Yijian Zhang, Yifan Lai, Jingwei Chen, Guangfu Wang, Weiming Tian

Materials Horizons· Volume 12· Issue 2
Publisher page

Abstract

Primary open-angle glaucoma (POAG) is the most common form of glaucoma and the leading cause of irreversible vision loss and blindness worldwide. Intraocular pressure (IOP) is the only modifiable risk factor, and prompt treatment to lower IOP can effectively slow the rate of vision loss due to glaucoma. Trabecular meshwork (TM) cells can maintain IOP homeostasis by correcting and adjusting the resistance to aqueous humor outflow in response to sustained pressure changes. TM cells' function is reduced, and membrane ion channels are impaired in POAG. The dysfunction of Large conductance Ca2+-activated K+ (BKCa) plays a central role in the pathogenesis of POAG. In this work, we targeted MXene nanoparticles (MXene-RGD) with piezoelectric response to TM cells in a 3D model of glaucoma in vitro as well as in the rabbit Transient Ocular Hypertension (OHT) Model in vivo. MXene-RGD gives the TM electromechanical transfer properties, while the self-enhancing and self-generated electricity properties of the TM are determined by the aqueous humor flow rate and the size of the deformation of the TM. MXene-RGD is nontoxic, as illustrated by a cell toxicity study and histological examination. In a 3D in vitro model of high-pressure glaucoma, whole-cell patch-clamp confirmed that piezoelectric stimulation turns on BKCa, which reduces the volume of the cell. MXene-RGD was injected into the anterior chamber with minimal trauma, i.e., anterior chamber injection, and specifically targeted to TM cells. The OHT model in vivo confirmed the potential IOP-lowering ability of MXene-RGD. We evaluated the ion channels involved in the reduction of IOP by MXene-RGD by pre-treatment with a BKCa channel blocker (iberiotoxin, IbTX) and a voltage-gated Ca2+channel blocker (nifedipine). Quantitative qPCR analysis showed that MXene-RGD inhibited the upregulation of mRNA expression levels of the myofibroblast marker α-smooth muscle actin (α-SMA) and the inflammatory response marker interleukin-6 (IL-6) induced by IOP. Histology confirmed that MXene-RGD attenuated IOP-induced proliferation and collagen production in the TM. Taken together, we present for the first time a minimally invasive surgical approach for targeting TM cells for POAG by utilizing piezoresponse nanomaterials to target BKCa to repair or awaken the ability of TM cells to regulate IOP homeostasis on their own.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Photoreceptor and optogenetics research · Retinal Development and Disorders

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Life Science and Technology, Harbin Institute of Technology, Harbin 150080, Heilongjiang Province, P. R. China

The First Affiliated Hospital, Harbin Medical University, 23 Youzheng Street, Harbin 150001, Heilongjiang Province, P. R. China

Funding

National Key Research and Development Program of China · China Postdoctoral Science Foundation

References (73)

Show source-provided references
1. George · Eye · 2022 · 36 · 209910.1038/s41433-021-01802-9 ↗
2. Garudadri · Ophthalmology · 2010 · 117 · 135210.1016/j.ophtha.2009.11.006 ↗
3. Dismuke · Am. J. Physiol.: Cell Physiol. · 2008 · 294 · C137810.1152/ajpcell.00363.2007 ↗
4. Jayaram · Lancet · 2023 · 402 · 178810.1016/S0140-6736(23)01289-8 ↗
5. Naik · Eur. J. Pharmacol. · 2020 · 881 · 17310.1016/j.ejphar.2020.173208 ↗
6. Acott · Prog. Retinal Eye Res. · 2021 · 82 · 10089710.1016/j.preteyeres.2020.100897 ↗
7. Rodriguez-Estevez · Gene Ther. · 2020 · 27 · 12710.1038/s41434-019-0105-4 ↗
8. Tanna · Ophthalmology · 2018 · 125 · 174110.1016/j.ophtha.2018.04.040 ↗
9. Berrino · Expert Opin. Ther. Pat. · 2019 · 29 · 81710.1080/13543776.2019.1670812 ↗
10. Wu · Curr. Drug Targets · 2024 · 25 · 9410.2174/0113894501286195231220094646 ↗
11. Stamer · Exp. Eye Res. · 2017 · 158 · 11210.1016/j.exer.2016.07.009 ↗
12. Kumar · PLoS One · 2013 · 8 · e7244710.1371/journal.pone.0072447 ↗
13. Ryskamp · Sci. Rep. · 2016 · 6 · 3058310.1038/srep30583 ↗
14. Mitchell · Am. J. Physiol. · 2002 · 283 · 31510.1152/ajpcell.00544.2001 ↗
15. Soto · Invest. Ophthalmol. Visual Sci. · 2004 · 45 · 365010.1167/iovs.04-0060 ↗
16. Bertrand · Invest. Ophthalmol. Visual Sci. · 2020 · 61 · 4110.1167/iovs.61.3.41 ↗
17. Du · Exp. Biol. Med. · 2020 · 245 · 18010.1177/1535370219892601 ↗
18. L.Nino-de-Rivera , D.Cervera and P.Castillo-Juarez , Ocular Hypertension-The Knowns and Unknowns , IntechOpen , 2021
19. Gasull · Sci. Rep. · 2019 · 9 · 539210.1038/s41598-019-41524-3 ↗
20. Dasso · Clin. Ophthalmol. · 2018 · 12 · 193910.2147/OPTH.S154001 ↗
21. Tanna · J. Glaucoma · 2020 · 29 · e4110.1097/IJG.0000000000001507 ↗
22. Wisely · Am. J. Ophthalmol. · 2020 · 217 · 2010.1016/j.ajo.2020.04.002 ↗
23. Hara · Cardiovasc. Drug Rev. · 2004 · 22 · 19910.1111/j.1527-3466.2004.tb00141.x ↗
24. Zhai · Acta Biomater. · 2021 · 125 · 4110.1016/j.actbio.2021.02.017 ↗
25. Dismuke · J. Ocul. Pharmacol. Ther. · 2009 · 25 · 30910.1089/jop.2008.0133 ↗
26. Wang · Science · 2007 · 316 · 10210.1126/science.1139366 ↗
27. Marino · ACS Nano · 2015 · 9 · 767810.1021/acsnano.5b03162 ↗
28. Kubanek · Sci. Rep. · 2016 · 6 · 2417010.1038/srep24170 ↗
29. Liu · Appl. Surf. Sci. · 2017 · 416 · 78110.1016/j.apsusc.2017.04.239 ↗
30. Tian · Nano Energy · 2022 · 101 · 10755610.1016/j.nanoen.2022.107556 ↗
31. Zhang · Composites, Part B · 2024 · 272 · 11119110.1016/j.compositesb.2024.111191 ↗
32. Lai · Nanoscale · 2015 · 7 · 1939010.1039/C5NR06513E ↗
33. Zhou · Cell Rep. Phys. Sci. · 2020 · 1 · 10014210.1016/j.xcrp.2020.100142 ↗
34. Zou · Adv. Funct. Mater. · 2023 · 33 · 221389510.1002/adfm.202213895 ↗
35. Tan · Nano Energy · 2021 · 90 · 10652810.1016/j.nanoen.2021.106528 ↗
36. Yue · Chem. Eng. J. · 2023 · 451 · 13868710.1016/j.cej.2022.138687 ↗
37. Gagen · Invest Ophthalmol. Visual Sci. · 2013 · 54 · 500010.1167/iovs.13-12084 ↗
38. Adhikari · Ind. Eng. Chem. Res. · 2021 · 60 · 1741710.1021/acs.iecr.1c02828 ↗
39. Cawkill · Drug Discovery Today · 2007 · 12 · 82010.1016/j.drudis.2007.08.014 ↗
40. Lee · Tissue Eng., Part B · 2008 · 14 · 6110.1089/teb.2007.0150 ↗
41. Wang · Colloid Interface Sci. Commun. · 2022 · 49 · 10063210.1016/j.colcom.2022.100632 ↗
42. Guo · Mol. Vision · 2012 · 18 · 1175
43. Malaki · Adv. Mater. · 2020 · 32 · 200315410.1002/adma.202003154 ↗
44. Cai · J. Nanobiotechnol. · 2022 · 20 · 46010.1186/s12951-022-01669-2 ↗
45. Anasori · Nat. Rev. Mater. · 2017 · 2 · 110.1038/natrevmats.2016.98 ↗
46. Luo · Adv. Funct. Mater. · 2021 · 31 · 210492810.1002/adfm.202104928 ↗
47. Peng · J. Mater. Chem. A · 2021 · 9 · 2507310.1039/D1TA06617J ↗
48. Pohanka · Int. J. Electrochem. Sci. · 2017 · 12 · 49610.20964/2017.01.44 ↗
49. Chen · Nat. Commun. · 2022 · 13 · 139110.1038/s41467-022-29087-w ↗
50. Jin · Chem. Eng. J. · 2020 · 380 · 12247510.1016/j.cej.2019.122475 ↗
51. Zhang · ACS Nano · 2020 · 14 · 346110.1021/acsnano.9b09549 ↗
52. Rastegardoost · Nano Energy · 2023 · 111 · 10836510.1016/j.nanoen.2023.108365 ↗
53. Song · ACS Appl. Mater. Interfaces · 2024 · 16 · 5063010.1021/acsami.4c08410 ↗
54. Jiang · Adv. Funct. Mater. · 2021 · 31 · 210538010.1002/adfm.202105380 ↗
55. Genchi · Adv. Healthcare Mater. · 2016 · 5 · 180810.1002/adhm.201600245 ↗
56. Marino · Nano Today · 2017 · 14 · 910.1016/j.nantod.2016.12.005 ↗
57. Li · Bioact. Mater. · 2022 · 18 · 399
58. Agarwal · Mol. Vision · 2015 · 21 · 612
59. Izzotti · Invest Ophthalmol. Visual Sci. · 2009 · 50 · 525110.1167/iovs.09-3871 ↗
60. Sahay · Invest Ophthalmol. Visual Sci. · 2017 · 58 · BIO10610.1167/iovs.17-21723 ↗
61. Saccà · ALTEX · 2020 · 37 · 26510.14573/altex.1909262e ↗
62. Poehlmann · J. Cell. Mol. Med. · 2013 · 17 · 161910.1111/jcmm.12150 ↗
63. Shen · Mol. Med. Rep. · 2020 · 22 · 160510.3892/mmr.2020.11198 ↗
64. Brayden · Science · 1992 · 256 · 53210.1126/science.1373909 ↗
65. Kong · Adv. Sci. · 2021 · 8 · 210096210.1002/advs.202100962 ↗
66. Heng · Smart Mater. Med. · 2022 · 3 · 410.1016/j.smaim.2021.11.003 ↗
67. Yarishkin · Front. Immunol. · 2022 · 13 · 80507610.3389/fimmu.2022.805076 ↗
68. Yarishkin · Vision Res. · 2024 · 224 · 10848710.1016/j.visres.2024.108487 ↗
69. Steinhausen · Exp. Eye Res. · 2000 · 70 · 28510.1006/exer.1999.0785 ↗
70. Xin · Exp. Eye Res. · 2017 · 158 · 17110.1016/j.exer.2016.06.007 ↗
71. Gao · Invest Ophthalmol. Visual Sci. · 2020 · 61 · 2110.1167/iovs.61.14.21 ↗
72. Jiang · Chin. J. Ophthalmol. · 1997 · 33 · 410
73. Lanzi · Int. J. Mol. Sci. · 2019 · 20 · 98110.3390/ijms20040981 ↗